2019
DOI: 10.1093/milmed/usy337
|View full text |Cite
|
Sign up to set email alerts
|

Pilot Study of a Novel Swine Model for Controlling Junctional Hemorrhage Using the iTClamp in Conjunction With Hemostatic Agents

Abstract: Exsanguinating hemorrhage is a primary cause of battlefield death. The iTClamp is a relatively new device (FDA approval in 2013) that takes a different approach to hemorrhage control by applying mechanism wound closure. However, no previous studies have explored the feasibility of utilizing the iTClamp in conjunction with hemostatic packing. To fill this important gap in the literature, a novel swine model was developed, and a total of 12 trials were performed using QuikClot Combat Gauze or XSTAT sponges in co… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
16
1

Year Published

2020
2020
2023
2023

Publication Types

Select...
4
3
1

Relationship

0
8

Authors

Journals

citations
Cited by 22 publications
(17 citation statements)
references
References 23 publications
0
16
1
Order By: Relevance
“…These ndings sharply contrasted with results generated with previous laboratory animal models that were given a compensatory stabilization period 14 . Therefore, to avoid decompensated hypotension before treatment, we ultimately selected the intervention point when MAP decreased by 30%.…”
Section: Discussioncontrasting
confidence: 95%
“…These ndings sharply contrasted with results generated with previous laboratory animal models that were given a compensatory stabilization period 14 . Therefore, to avoid decompensated hypotension before treatment, we ultimately selected the intervention point when MAP decreased by 30%.…”
Section: Discussioncontrasting
confidence: 95%
“…Exsanguinating hemorrhage is the leading cause of preventable causes of death in the combat setting and over one-third of those cases are due to extremity or junctional injuries [1]. Due to several factors including routine wear of body armor, judicious use of tourniquets for extremity hemorrhage,the mortality from truncal and peripheral-extremity hemorrhage has decreased relatively [2].…”
Section: Introductionmentioning
confidence: 99%
“…In order to control junctional bleeding and prevent deaths, development led to newly FDA-cleared junctional tourniquets and hemostatic agents [1,[5][6]]. To date, there have been lots of literature comparing the hemostatic properties of these devices and materials [2,[7][8][9][10][11].…”
Section: Introductionmentioning
confidence: 99%
“…Exsanguinating hemorrhage is the leading cause of preventable deaths in combat settings, and over one-third of those cases are due to extremity or junctional injuries [1]. Due to several factors including routine wear of body armor and judicious use of tourniquets for extremity hemorrhage, mortality rates associated with truncal and peripheral-extremity hemorrhage have relatively decreased [2].…”
Section: Introductionmentioning
confidence: 99%
“…Advanced hemostatic agents or junctional tourniquets applied to wounds that are not amenable to treatment with a routine tourniquet have become the focus of research. Novel junctional tourniquets and hemostatic agents have been developed and approved by regulators to control junctional bleeding and prevent deaths [1,[5][6]. Several studies have examined the hemostatic properties of these devices and materials [2,[7][8][9][10][11].…”
Section: Introductionmentioning
confidence: 99%